HWAM
LXRX icon

Hennion & Walsh Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-848,138
Closed -$1.32M – 988
2026
Q1 		$1.32M Sell
848,138
-53,084
-6% -$77.2K 0.04% 446
2025
Q4 		$1.04M Buy
901,222
+122,010
+16% +$168K 0.04% 506
2025
Q3 		$1.05M Sell
779,212
-14,188
-2% -$16.1K 0.04% 501
2025
Q2 		$750K Sell
793,400
-36,654
-4% -$23.7K 0.03% 561
2025
Q1 		$382K Sell
830,054
-33,201
-4% -$20.9K 0.02% 708
2024
Q4 		$638K Buy
863,255
+132,117
+18% +$159K 0.03% 572
2024
Q3 		$1.15M Buy
731,138
+188,239
+35% +$335K 0.05% 417
2024
Q2 		$912K Buy
+542,899
New +$974K 0.05% 446

Other funds holding LXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $429M AUM 52.52% 1-Year Est. Return

Hennion & Walsh Asset Management's LXRX Position: Q2 2026 in Review

Hennion & Walsh Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 848,138 shares — an estimated $1.32M sold.

Hennion & Walsh Asset Management first reported a position in LXRX in Q2 2024 and held it in 8 quarters. The position peaked at $1.32M in Q1 2026. 59 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Hennion & Walsh Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 848,138 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $1.32M.
  • Hennion & Walsh Asset Management first reported a position in Lexicon Pharmaceuticals in Q2 2024 and held it in 8 quarters.
  • Hennion & Walsh Asset Management's Lexicon Pharmaceuticals position peaked at $1.32M in Q1 2026.
  • 59 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.